Prof. Albiges shares LITESPARK-005 study results: Belzutifan improves PFS in pretreated mRCC patients

In this podcast, UROONCO RCC associate editor Dr. Teele Kuusk (GB) talks with medical oncologist Prof. Laurence Albiges (FR), Head of the Department of Oncology at Gustave Roussy, about her abstract: Belzutifan versus everolimus in participants with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomised open-label phase III LITESPARK-005 study.Prof. Albiges discusses the study results she presented at ESMO 2023. LITESPARK-005 established HIF-2a inhibition as a novel t...